

Onyx pharma - In the Driver's Seat, with Kyprolis Approval

<https://marketpublishers.com/r/O9088DBEF04EN.html>

Date: August 2012

Pages: 3

Price: US\$ 90.00 (Single User License)

ID: O9088DBEF04EN

Abstracts

An 'Accelerated approval' of Kyprolis (carfilzomib – CFZ, R, next-generation proteasome inhibitor) and better positioning of Nexavar (L, RCC, HCC, partnered with Bayer) in HCC after the setback to Brivanib (BMS, HCC) have swung the wind in Onyx's (ONXX) favor. Kyprolis has the first mover advantage in catering to the unmet need in Relapsed and Refractory Multiple Myeloma – R/R MM. In the 2Q12, Nexavar reported modest growth of 4% (YoY) where sales grew 13% (YoY) in the US and flat growth in the ROW due to Fx impact, pricing pressure, rebates and healthcare reforms. ONXX has revised its FY12 guidance – increased costs with no change in sales guidance (Net product revenues: \$840m-\$860m). We see modest growth in... For more detail, please read our report released on 9th Aug. 2012, on Onyx Pharma titled "In the Driver's Seat, with Kyprolis Approval".

I would like to order

Product name: Onyx pharma - In the Driver's Seat, with Kyprolis Approval

Product link: <https://marketpublishers.com/r/O9088DBEF04EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O9088DBEF04EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970